Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA) are set for more legal battles over their rival COVID-19 vaccines after London’s High Court delivered a mixed ruling on two of Moderna’s patents. This decision is likely to trigger a series of appeals in the ongoing London litigation. Pfizer and its German partner BioNTech SE (NASDAQ:BNTX) initiated the lawsuit against Moderna in London in September 2022, seeking to revoke two of Moderna’s patents. In response, Moderna accused Pfizer and BioNTech of infringing on its patents. These lawsuits are part of a global legal struggle over messenger RNA (mRNA) technology. Read Next: